ARCC

Business Context and Reporting Period

Ares Capital Corporation (ARCC) is a closed-end, non-diversified management investment company regulated as a Business Development Company (BDC) under the Investment Company Act of 1940. The company is externally managed by Ares Capital Management LLC. Its investment objective is to generate current income and capital appreciation primarily through debt investments (first and second lien senior secured loans, mezzanine debt) and, to a lesser extent, equity investments in middle-market companies.

Reporting Period: Quarterly report (Form 10-Q) for the period ended September 30, 2014.

Key Financial Metrics

Material Changes vs. Prior Period

• Investment Income Growth: Total investment income increased to $253.4 million for the three months ended September 30, 2014, from $246.8 million in the same period in 2013. This was primarily driven by an increase in the portfolio size (average amortized cost increased from $7.0 billion to $8.2 billion) and higher capital structuring service fees due to increased new investment commitments.
• Net Investment Income Decline: Despite higher revenue, Net Investment Income decreased to $105.3 million from $126.2 million year-over-year. This decline was caused by a significant increase in operating expenses, specifically a rise in capital gains incentive fees (accrued under GAAP) from $2.9 million to $13.1 million and higher interest and credit facility fees ($54.1 million vs. $44.4 million) due to increased debt levels.
• Realized Gains Surge: Net realized gains on investments jumped to $76.5 million for the quarter from $8.9 million in the prior year period. Major contributors included exits from Insight Pharmaceuticals Corporation ($33.1 million) and The Dwyer Group ($21.1 million).
• Unrealized Gains/Losses: The company reported net unrealized losses of $4.1 million for the quarter, compared to net unrealized gains of $5.6 million in the prior year period. However, for the nine-month period, net unrealized gains were $87.9 million, a significant increase from $6.5 million in the prior year.
• Debt Expansion: Total debt outstanding increased to $3.68 billion (carrying value) from $2.99 billion at December 31, 2013, reflecting increased leverage to fund portfolio growth.

Guidance, Outlook, and Risks

• Management Commentary: Management highlighted that the increase in interest income was driven by portfolio growth. The capital gains incentive fee accrual increased due to higher net gains on investments, though no fee was actually payable under the investment advisory agreement as of the period end. The company continues to focus on generating current income and capital appreciation.
• Recent Developments: The company received a "green light" from the Small Business Administration (SBA) to proceed with an application for a Small Business Investment Company (SBIC) license, which could provide an incremental source of long-term debt capital if approved.
• Investment Activity (Post-Period): Between October 1 and October 29, 2014, the company made $317 million in new investment commitments and exited $456 million of commitments, recognizing approximately $22 million in net realized gains.
• Risks and Contingencies:
  • Valuation Risk: Substantially all investments are valued using unobservable inputs (Level 3). Fair values may differ materially from amounts ultimately realized, especially in a forced liquidation.
  • Legal Proceedings: The company is a defendant in an action filed by the bankruptcy trustee of DSI Renal Holdings LLC, alleging fraudulent transfer. The plaintiff seeks approximately $117 million in damages from the company. Management believes the claims are without merit.
  • Non-Accrual Status: As of September 30, 2014, 2.2% of total investments at amortized cost were on non-accrual status, down from 3.1% at year-end 2013.

Key Facts for Investor Verification

• Capital Gains Fee Accrual: Verify the distinction between the GAAP accrual of capital gains incentive fees ($87.7 million payable liability) and the actual fee payable under the advisory agreement ($0 as of period end).
• Portfolio Concentration: Review the Senior Secured Loan Program (SSLP) co-investment with GE, which represented approximately 22.6% of the total investment portfolio at fair value.
• Debt Covenants: Confirm continued compliance with the 200% asset coverage ratio requirement under the Investment Company Act (currently at 243%) and borrowing base restrictions on revolving facilities.
• Realized Gains Quality: Assess the sustainability of the $76.5 million in quarterly realized gains, noting they were driven by specific exits (Insight Pharmaceuticals, The Dwyer Group) rather than broad portfolio appreciation.
• Non-Accrual Trends: Monitor the reduction in non-accrual loans from 3.1% to 2.2% and the specific portfolio companies contributing to credit risk (e.g., Instituto de Banca y Comercio, Inc. in the SSLP).